Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection

Hepatology Research

Volumn 36, Issue 4, 2006, Pages 272-276

  Shinkai, Noboru ^a   Tanaka, Yasuhiro ^a   Orito, Etsuro ^a   Ito, Kiyoaki ^a   Ohno, Tomoyoshi ^b   Hirashima, Noboru ^b   Hasegawa, Izumi ^b   Sugauchi, Fuminaka ^a,b   Ueda, Ryuzo ^a   Mizokami, Masashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b CHUKYO HOSPITAL   (Japan)

Author keywords

Chronic hepatitis B virus infection; Hepatitis B virus; Hepatitis B virus core related antigen; Lamivudine

Indexed keywords

AMINOTRANSFERASE; HEPATITIS B CORE ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; AGE; AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; ENZYME REACTIVATION; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; JAPAN; LIVER CIRRHOSIS; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; RELAPSE; SEX; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VIRUS DETECTION;

EID: 33750890637     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2006.08.005     Document Type: Article

References (18)

1. Lai C.L., Ratziu V., Yuen M.F., et al. Viral hepatitis B. Lancet 362 9401 (2003) 2089-2094
2. Beasley R.P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61 10 (1988) 1942-1956
3. Lok A.S., Heatheote E.J., and Hoofnagle J.H. Management of hepatitis B: summary of a workshop. Gastrogeterology 122 (2002) 2092-2093
4. Chayama K., Suzuki Y., Kobayashi M., et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27 6 (1998) 1711-1716
5. Lau D.T., Khokhar M.F., Doo E., et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32 4 Pt 1 (2000) 828-834
6. Liaw Y.F., Leung N.W., Chang T.T., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119 1 (2000) 172-180
7. Hadziyannis S.J., Papatheodoridis G.V., Dimou E., et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32 4 Pt 1 (2000) 847-851
8. Liaw Y.F., Chien R.N., Yeh C.T., Tsai S.L., et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30 2 (1999) 567-572
9. Allen M.I., Deslauriers M., Andrews C.W., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27 6 (1998) 1670-1677
10. Honkoop P., de Man R.A., Niesters H.G., et al. Clinical impact of lamivudine resistance in chronic hepatitis B. J Hepatol 29 3 (1998) 510-511
11. Andreone P., Gramenzi A., Cursaro C., et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 11 5 (2004) 439-442
12. Conjeevaram H.S., and Lok A.S. Management of chronic hepatitis B. J Hepatol 38 Suppl 1 (2003) S90-S103
13. Ito K., Tanaka Y., Orito E., et al. Predicting relapse after cessation of lamivudine monotherapy for chronic hepatitis B virus infection. Clin Infect Dis 38 4 (2004) 490-495
14. Kimura T., Rokuhara A., Sakamoto Y., et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 40 2 (2002) 439-445
15. Rokuhara A., Tanaka E., Matsumoto A., et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. J Viral Hepat 10 4 (2003) 324-330
16. Tanaka E., Matsumoto A., Suzuki F., et al. Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. Liver Int 26 1 (2006) 90-96
17. Wolters L.M., Hansen B.E., Niesters H.G., et al. Viral dynamics in chronic hepatitis B patients during lamivudine therapy. Liver 22 2 (2002) 121-126
18. Kimura T., Ohno N., Terada N., et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem 280 23 (2005) 21713-21719